Skip to main content
. 2007 Aug 8;81(20):11489–11498. doi: 10.1128/JVI.02845-06

FIG. 1.

FIG. 1.

Antiviral activity of RCP168. (A) RCP168 was more potent in blocking HIV-1 entry than SDF-1α and was highly selective in blocking T-tropic HIV-1 strains by single-round virus inhibition assays. (B) The strong antiviral activity of RCP168 was also demonstrated by virus infection assays. (C) RCP168 showed antiviral effects comparable to those of the T20 peptide, a recently approved drug targeting viral gp41 protein-mediated HIV-1 entry. The error bars indicate standard deviations.